XML 15 R5.htm IDEA: XBRL DOCUMENT v3.22.1
STATEMENTS OF CHANGES IN REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY (DEFICIT) (UNAUDITED) - USD ($)
$ in Thousands
Total
Preferred stock
Redeemable Convertible Preferred Stock
Common Stock
Additional Paid-In Capital
Accumulated Deficit
Accumulated Other Comprehensive Loss
Increase (Decrease) in Stockholders' Equity            
Beginning balance, shares     17,887,631      
Beginning balance at Dec. 31, 2020   $ 156,433        
Beginning balance, shares at Dec. 31, 2020   13,752,043        
Increase (Decrease) in Temporary Equity            
Issuance of Series E preferred stock, net of issuance costs   $ 4,944        
Issuance of Series E preferred stock, net of issuance costs, shares   254,886        
Ending balance at Mar. 31, 2021   $ 161,377        
Ending balance, shares at Mar. 31, 2021   14,006,929        
Beginning balance at Dec. 31, 2020 $ (89,428)   $ 2 $ 635 $ (90,065) $ 0
Increase (Decrease) in Stockholders' Equity            
Issuance of restricted stock, shares     703,425      
Stock-based compensation 1,519     1,519    
Issuance of shares in acquisition of Denovium 368     368    
Issuance of shares in acquisition of Denovium, shares     1,010,296      
Net loss (10,962)       (10,962)  
Ending balance at Mar. 31, 2021 (98,503)   $ 2 2,522 (101,027) 0
Ending balance, shares at Mar. 31, 2021     19,601,352      
Increase (Decrease) in Stockholders' Equity            
Beginning balance, shares     19,601,352      
Beginning balance, shares     92,648,036      
Beginning balance at Dec. 31, 2021   $ 0        
Beginning balance, shares at Dec. 31, 2021   0        
Ending balance at Mar. 31, 2022   $ 0        
Ending balance, shares at Mar. 31, 2022   0        
Beginning balance at Dec. 31, 2021 366,107   $ 9 557,136 (191,025) (13)
Increase (Decrease) in Stockholders' Equity            
Issuance of shares upon option exercise 213     213    
Issuance of shares upon option exercise, shares     187,151      
Stock-based compensation 3,680     3,680    
Foreign currency translation adjustments (10)         (10)
Net loss (29,494)       (29,494)  
Ending balance at Mar. 31, 2022 $ 340,496   $ 9 $ 561,029 $ (220,519) $ (23)
Ending balance, shares at Mar. 31, 2022     92,835,187      
Increase (Decrease) in Stockholders' Equity            
Beginning balance, shares     92,835,187